News

Phase 2 trial tests azacitidine plus venetoclax in therapy-related high-risk MDS, showing remissions and better post-transplant survival despite TP53 mutations.

During a virtual event, Aditya Bardia, MD, MPH and participants weigh elacestrant and imlunestrant, comparing real-world adverse effects and efficacy.

FDA clears mRNA-based HPV test for primary screening, helping clinicians spot cancer-driving infections, cut overtreatment, and personalize care.

FDA fast-tracks pelareorep with bevacizumab and FOLFIRI for KRAS-mutant MSS metastatic colorectal cancer, after standout response and survival signals.

TNBC care shifts to TROP2 ADCs plus immunotherapy, highlighting early relapse needs, sequencing dilem

A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need for improved access to targeted therapies.

During his presentation at the 4th Annual Miami Cancer Institute Precision Oncology Symposium, Petros Grivas, MD, PhD, FASCO, provided a detailed roadmap for community oncologists with an emphasis on precision medicine.

FDA reviews new drug applications for rivoceranib and camrelizumab as first-line treatments for advanced liver cancer, promising improved survival rates.

FDA prioritizes review of datopotamab deruxtecan for treating metastatic triple-negative breast cancer, showing significant survival benefits over chemotherapy.

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Discover the latest advancements in pancreatic cancer treatment, including targeted therapies and next-generation sequencing, transforming patient care and outcomes.

The FDA granted orphan drug designation to IFx-2.0, an injection designed to enhance immune response, in cutaneous melanoma.

Gemogenovatucel-T shows remarkable survival benefits in high-risk ovarian cancer patients, highlighting its potential as a new standard of care.

FDA reviews zanzalintinib and atezolizumab for metastatic colorectal cancer, offering hope for patients with limited treatment options.

FDA fast-tracks QTX-2101, an oral arsenic trioxide therapy, enhancing treatment accessibility for acute promyelocytic leukemia patients.

New data reveals CD47 expression as a key biomarker for predicting evorpacept's effectiveness in treating HER2-positive metastatic breast cancer.

Discover how antibody-drug conjugates (ADCs) are transforming treatment strategies for gastrointestinal cancers, enhancing precision and patient outcomes.

January 2026 marks a pivotal month in oncology, with the FDA advancing numerous innovative therapies for challenging cancers, emphasizing precision medicine.

Discover the latest FDA approvals and groundbreaking trial results in cancer treatments, including myeloma, pancreatic cancer, and melanoma advancements.

BioInvent's BI-1808 combined with pembrolizumab shows promising antitumor activity in recurrent ovarian cancer, offering hope for better treatment options.

The LARA trial reveals promising results for pembrolizumab and lenvatinib in treating recurrent clear cell gynecological cancer, showcasing effective antitumor activity.

New research uncovers how genetic ancestry influences head and neck cancer biology, paving the way for personalized treatment strategies and improved patient outcomes.

Neoadjuvant pembrolizumab showed promising high response rates and melanoma-specific survival outcomes in desmoplastic melanoma.

Lirafugratinib shows promise as a second-line treatment for cholangiocarcinoma, achieving significant response rates and durable outcomes in clinical trials.

A large-scale analysis reveals novel predictors of survival and resistance mechanisms in metastatic breast cancer treated with T-DXd, enhancing patient stratification.

A novel granule formulation of selumetinib shows promise for treating pediatric patients with inoperable neurofibromatosis type 1-related tumors, enhancing medication accessibility.